The Effects of the Endocrine System on Endometrial Cancer (Ghrelin)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Information provided by (Responsible Party):
Queensland Centre for Gynaecological Cancer
ClinicalTrials.gov Identifier:
NCT01075386
First received: February 23, 2010
Last updated: September 7, 2014
Last verified: September 2014
  Purpose

Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.


Condition
Endometrial Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer

Resource links provided by NLM:


Further study details as provided by Queensland Centre for Gynaecological Cancer:

Biospecimen Retention:   Samples Without DNA

Endometrial tissue


Estimated Enrollment: 80
Study Start Date: October 2009
Estimated Study Completion Date: December 2014
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Grade 2
Patients with Endometrial cancer of Grade 1 differentiation
Benign
Patients without endometrial cancer
Grade 1
Patients with Endometrial cancer of Grade 2 differentiation
Grade 3
Patients with Endometrial cancer of Grade 3 differentiation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with endometrial cancer and patients who are having a hysterectomy for non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine bleeding are eligible for the study

Criteria

Inclusion Criteria:

  • women aged 18 years or older
  • having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
  • have provided informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01075386

Locations
Australia, Queensland
Greenslopes Private Hospital
Greenslopes, Queensland, Australia, 4120
Sponsors and Collaborators
Queensland Centre for Gynaecological Cancer
Greenslopes Private Hospital
The University of Queensland
Sullivan and Nicolaides Pathology
Investigators
Study Chair: Chen Chen, MD PhD The University of Queensland
  More Information

No publications provided

Responsible Party: Queensland Centre for Gynaecological Cancer
ClinicalTrials.gov Identifier: NCT01075386     History of Changes
Other Study ID Numbers: Endo01
Study First Received: February 23, 2010
Last Updated: September 7, 2014
Health Authority: Australia: National Health and Medical Research Council
Australia: Department of Health and Ageing Therapeutic Goods Administration
Australia: Human Research Ethics Committee

Keywords provided by Queensland Centre for Gynaecological Cancer:
Hysterectomy
Endometrial cancer
Benign
Endocrine system
Tissue collection

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on September 16, 2014